Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|June 25, 2020

CHMP Recommends EU Authorization of Remdesivir for COVID-19

The European Medicines Agency’s (EMA’s) Committee for Human and Medicinal Products (CHMP) has recommended Veklury (remdesivir) be granted conditional marketing authorization in the European Union for the treatment of COVID-19.

The European Medicines Agency’s (EMA’s) Committee for Human and Medicinal Products (CHMP) has recommended Veklury (remdesivir) be granted conditional marketing authorization in the European Union for the treatment of COVID-19.

According to a June 25, 2020 press release, CHMP began assessing data on quality and manufacturing, non-clinical data, preliminary clinical data, and supporting safety data from compassionate use programs of remdesivir since April 30, 2020. All of this information has been provided in advance of the submission of the marketing authorization application (June 5, 2020) and has been implemented into a rolling review procedure, which has been adopted by EMA in light of the current pandemic situation.

The majority of the information that CHMP used to make its decision came from the NIAID-ACTT-1 study, which demonstrated an improvement in recovery rate for patients with advanced COVID-19, compared with placebo. The EC will now fast-track its decision on the conditional marketing authorization for remdesivir, which is expected in the next seven days. 

Gilead Sciences (developer of Veklury) will be required to submit final reports of the remdesivir studies to EMA by December 2020 so that the drug’s efficacy and safety can be better characterized.

Source: EMA

 

 

Related to this article

View more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more